Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-targeted CAR-T Cells in Castration-resistant Prostate Cancer
NCT05354375Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Dec 2022
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in prostate cancer (PCa) (4 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Incidence and Severity of Adverse Events at 1 month and Effectiveness Evaluation at 3 months. Started Dec 2022; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05354375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354375.